Status and phase
Conditions
Treatments
About
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion criteria
Biopsy proven aggressive non-hodgkin's lymphoma
Relapsed or refractory to previous therapy for lymphoma
At least one prior combination chemotherapy regime
Measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter
Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2
Willing to follow the pregnancy precautions
Key Exclusion criteria
Any of the following laboratory abnormalities.
Subjects who are candidates for and willing to undergo an autologous stem cell transplant.
History of active Central Nervous System (CNS) lymphoma within the previous 6 months
History of other malignancies within the past year
Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C
Primary purpose
Allocation
Interventional model
Masking
217 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal